Health Care & Life Sciences » Pharmaceuticals » Top pharmaceutical drugs | Top 20 neurology products by U.S. revenue 2016

Revenue of top 20 neurology products in the United States 2016

Top 20 neurology products in the U.S. based on revenue in 2016 (Figures expressed in millions of U.S. dollars, unless otherwise specified)

The data shows the projected top 20 products for neurology diseases based on revenue in the U.S. during 2016. In that year, Abilify, an Otsuka product, is expected to generate approx. 322 million USD in revenues, a decrease of some 1.7 billion dollars compared to 2014, caused by patent loss.

Copaxone (Teva)	3171
Tecfidera (Biogen)	3118
Gilenya (Novartis	1714
Avonex (Biogen)	1685
Invega Sustenna (Janssen)	1304
Latuda (Sunovion)	1286
Tysabri (Biogen)	1179
Rebif (Pfizer)	1084
Aubagio (Sanofi)	923
Namenda XR (Allergan)	682
Seroquel XR (AstraZeneca)	633
Pristiq (Pfizer)	516
Ampyra (Acorda)	479
Abilify Maintena (Otsuka)	428
Betaseron (Bayer)	420
Risperdal Consta (J&J)	380
Abilify (Otsuka)	322
Plegridy (Biogen)	315
Trintellix (Takeda)	297
Wellbutrin XL (Valeant)	279

Revenue of top 20 neurology products in the United States 2016

StatInvestor